Drug pricing regulator NPPA asks state drug controllers to submit action-taken reports by November 16 as a 30 per cent trade margin cap on 137 cancer drugs takes effect
The revised scheme removes the minimum sales threshold, lowers investment requirements and offers higher incentives for critical components and advanced medical devices
The Union Health Ministry has proposed tightening microbial contamination limits in Grade A clean areas to align India's pharmaceutical manufacturing standards with WHO guidelines
Hyderabad-based HRV Pharma acquires German clinical trial supplier Phatebo, which reported ₹350 crore revenue in 2025, marking its entry into Europe's finished formulations business
Domestic manufacturers want importers' margins included in a uniform trade margin framework for medical devices, with a pilot covering high-volume consumables such as IV sets
Drug regulators in Maharashtra, Karnataka and Uttar Pradesh are gathering data on price mark-ups, potentially strengthening the case for a review of trade margin rationalisation
The top 10 in August included Sun Pharma, Cipla, Abbott, Mankind Pharma, Torrent Pharmaceuticals, Alkem Laboratories, Intas Pharmaceuticals, Lupin, Zydus Lifesciences and Dr Reddy's Laboratories
Authorities are tracing an alleged interstate fake medicine network after a raid in Bidadi uncovered suspected counterfeit and expired drugs worth ₹5 crore
Kaisha Pharma will manufacture ampoules, vials, prefilled syringes and cartridges, while targeting Indian and global pharmaceutical and biotechnology companies
Rubicon's share price hit a new high of ₹1,800 soaring 11 per cent on the BSE in Monday's intra-day deals amid heavy volume after reporting healthy earnings for Q1FY27.
GSK India aims to double revenue to ₹8,000 crore by FY30, with oncology and adult vaccines emerging as key growth drivers alongside its general-medicines portfolio
India's pharma industry must pivot from global leadership in generics to innovation, backed by stronger policy, R&D funding and regulatory reforms, says Satish Reddy
Emcure expects overseas markets to drive growth in FY27 through product approvals, differentiated offerings and capacity expansion, while domestic business is seen improving
USFDA has granted final approval to Zydus Lifesciences' generic version of IC-Green, an imaging agent used in vascular, transplant and cancer surgeries.
Strong custom synthesis growth, peptide opportunities and higher earnings estimates support Divi's outlook, but elevated valuations could restrict further stock upside